Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hammerer

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
BJU International|March 29, 2006
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancerNicolas Mottet, Tommaso Prayer-Galetti, Peter Hammerer, et al.
The Journal of Urology|July 2, 2014
Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registriesAhmad Haider, Michael Zitzmann, Gheorghe Doros, et al.
European Urology|August 6, 2002
Patient-reported sexual function after nerve-sparing radical retropubic prostatectomyJoachim Noldus, Uwe Michl, Markus Graefen, et al.
The Prostate|March 10, 2009
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefitsFrancesco Montorsi, Antonio Alcaraz, François Desgrandchamps, et al.
The Prostate|March 3, 2004
Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomyAlbrecht Röpke, Andreas Erbersdobler, Peter Hammerer, et al.
BJU International|July 31, 2007
The role of intermittent androgen deprivation in prostate cancerLaurent Boccon-Gibod, Peter Hammerer, Stephan Madersbacher, et al.
The Prostate|March 18, 2003
Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zonesHerbert Augustin, Andreas Erbersdobler, Markus Graefen, et al.
World Journal of Urology|January 7, 2018
PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime studyPeter Hammerer, Salah-Eddin Al-Batran, Christine Windemuth-Kieselbach, et al.
Aktuelle Urologie|November 21, 2019
[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany]Marie Christine Hupe, Peter Hammerer, Miriam Ketz, et al.
European Urology|February 5, 2003
Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002Herbert Augustin, Peter Hammerer, Markus Graefen, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
BJU International|March 29, 2006
Optimizing outcomes and quality of life in the hormonal treatment of prostate cancerNicolas Mottet, Tommaso Prayer-Galetti, Peter Hammerer, et al.
The Journal of Urology|July 2, 2014
Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registriesAhmad Haider, Michael Zitzmann, Gheorghe Doros, et al.
European Urology|August 6, 2002
Patient-reported sexual function after nerve-sparing radical retropubic prostatectomyJoachim Noldus, Uwe Michl, Markus Graefen, et al.
The Prostate|March 10, 2009
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefitsFrancesco Montorsi, Antonio Alcaraz, François Desgrandchamps, et al.
The Prostate|March 3, 2004
Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomyAlbrecht Röpke, Andreas Erbersdobler, Peter Hammerer, et al.
BJU International|July 31, 2007
The role of intermittent androgen deprivation in prostate cancerLaurent Boccon-Gibod, Peter Hammerer, Stephan Madersbacher, et al.
The Prostate|March 18, 2003
Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zonesHerbert Augustin, Andreas Erbersdobler, Markus Graefen, et al.
World Journal of Urology|January 7, 2018
PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime studyPeter Hammerer, Salah-Eddin Al-Batran, Christine Windemuth-Kieselbach, et al.
Aktuelle Urologie|November 21, 2019
[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany]Marie Christine Hupe, Peter Hammerer, Miriam Ketz, et al.
European Urology|February 5, 2003
Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002Herbert Augustin, Peter Hammerer, Markus Graefen, et al.
Pageof 6